Statin for the Primary Prevention of Cardiovascular Disease in Patients with Diabetes Mellitus

Overview

Journal Diabetes Metab J

Specialty Endocrinology

Date 2014 Mar 15

PMID 24627825

Citations 8

Authors

Bo Kyung Koo

Affiliations

Soon will be listed here.

Citing Articles

Effect of statins and antihyperglycemics on chronic kidney disease in patients with type 2 diabetes mellitus: a retrospective cohort study with a 12-year follow-up.

Jairoun A, Ping C, Ibrahim B, Al Jawamis D, Al Jaberi A, Dawoud T J Pharm Policy Pract. 2025; 18(1):2414293.

PMID: 39776464 PMC: 11703420. DOI: 10.1080/20523211.2024.2414293.

Hypecotumines A-D, new isoquinoline alkaloids with potential PCSK9 inhibition activity from Hypecoum erectum L.

Wei Y, Wen H, Yang L, Zhang B, Li X, Li S Nat Prod Bioprospect. 2024; 14(1):57.

PMID: 39404968 PMC: 11480295. DOI: 10.1007/s13659-024-00479-3.

Phenotyping of Korean patients with better-than-expected efficacy of moderate-intensity statins using tensor factorization.

Choi J, Kim Y, Kim H, Choi I, Yu H PLoS One. 2018; 13(6):e0197518.

PMID: 29897980 PMC: 5999101. DOI: 10.1371/journal.pone.0197518.

Comparison between Atorvastatin and Rosuvastatin in Renal Function Decline among Patients with Diabetes.

Han E, Kim G, Lee J, Lee Y, Kim B, Lee B Endocrinol Metab (Seoul). 2017; 32(2):274-280.

PMID: 28685516 PMC: 5503873. DOI: 10.3803/EnM.2017.32.2.274.

PCSK9 as a therapeutic target for cardiovascular disease.

Zhang P Exp Ther Med. 2017; 13(3):810-814.

PMID: 28450903 PMC: 5403434. DOI: 10.3892/etm.2017.4055.

References

Lee S, Kwon H, Park Y, Ko S, Choi Y, Yoon K . Statin Discontinuation after Achieving a Target Low Density Lipoprotein Cholesterol Level in Type 2 Diabetic Patients without Cardiovascular Disease: A Randomized Controlled Study. Diabetes Metab J. 2014; 38(1):64-73. PMC: 3950197. DOI: 10.4093/dmj.2014.38.1.64. View

Taylor F, Huffman M, Macedo A, Moore T, Burke M, Davey Smith G . Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013; (1):CD004816. PMC: 6481400. DOI: 10.1002/14651858.CD004816.pub5. View

Ridker P, Danielson E, Fonseca F, Genest J, Gotto Jr A, Kastelein J . Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359(21):2195-207. DOI: 10.1056/NEJMoa0807646. View

Taylor F, Ward K, Moore T, Burke M, Davey Smith G, Casas J . Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011; (1):CD004816. PMC: 4164175. DOI: 10.1002/14651858.CD004816.pub4. View

Haffner S, Lehto S, Ronnemaa T, Pyorala K, Laakso M . Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339(4):229-34. DOI: 10.1056/NEJM199807233390404. View

Pyorala K, Pedersen T, Kjekshus J, Faergeman O, Olsson A, Thorgeirsson G . Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997; 20(4):614-20. DOI: 10.2337/diacare.20.4.614. View

Stone N, Robinson J, Lichtenstein A, Merz C, Blum C, Eckel R . 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 63(25 Pt B):2889-934. DOI: 10.1016/j.jacc.2013.11.002. View

. Standards of medical care in diabetes--2014. Diabetes Care. 2013; 37 Suppl 1:S14-80. DOI: 10.2337/dc14-S014. View

Colhoun H, Betteridge D, Durrington P, Hitman G, Neil H, Livingstone S . Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004; 364(9435):685-96. DOI: 10.1016/S0140-6736(04)16895-5. View

10.

Kearney P, Blackwell L, Collins R, Keech A, Simes J, Peto R . Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008; 371(9607):117-25. DOI: 10.1016/S0140-6736(08)60104-X. View

11.

Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes E . The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012; 380(9841):581-90. PMC: 3437972. DOI: 10.1016/S0140-6736(12)60367-5. View

12.

Carter A, Gomes T, Camacho X, Juurlink D, Shah B, Mamdani M . Risk of incident diabetes among patients treated with statins: population based study. BMJ. 2013; 346:f2610. PMC: 3662830. DOI: 10.1136/bmj.f2610. View

13.

Collins R, Armitage J, Parish S, Sleigh P, Peto R . MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003; 361(9374):2005-16. DOI: 10.1016/s0140-6736(03)13636-7. View

14.

Raikou M, McGuire A, Colhoun H, Betteridge D, Durrington P, Hitman G . Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia. 2007; 50(4):733-40. DOI: 10.1007/s00125-006-0561-4. View

15.

Ray K, Seshasai S, Erqou S, Sever P, Jukema J, Ford I . Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med. 2010; 170(12):1024-31. DOI: 10.1001/archinternmed.2010.182. View